Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity

Clinical Colorectal Cancer

Volumn 12, Issue 1, 2013, Pages 8-14

  Deboever, Guido ^a   Hiltrop, Nick ^b   Cool, Mike ^a   Lambrecht, Guy ^a  

^a Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Fluoropyrimidine induced toxicity; Raltitrexed; S 1

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CETUXIMAB; CYTOCHROME P450 2A6; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLYCERYL TRINITRATE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RALTITREXED; UFT;

ANGINA PECTORIS; AREA UNDER THE CURVE; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOGENIC SHOCK; CARDIOTOXICITY; COLON CANCER; COLON METASTASIS; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; ECHOCARDIOGRAPHY; ETHNIC DIFFERENCE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PATHOGENESIS; RECURRENCE RISK; REVIEW; SIDE EFFECT; SUDDEN DEATH; TAKOTSUBO CARDIOMYOPATHY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874750769     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.09.003     Document Type: Review

References (78)

1. P. Thirion, S. Michiels, J.P. Pignon Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: un updated analysis [published erratum appears in J Clin Oncol 2005;23:1377-8] J Clin Oncol 22 2004 3766 3775
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Meta-analysis Group In Cancer J Clin Oncol 16 1998 301 308
3. E. Chu, C. Eng, J. Abbruzzese et al. Efficacy and safety of capecitabine for colorectal cancer Am J Oncol Rev 2 suppl 3 2003 1 28
4. J. Cassidy, S. Clarke, E. Díaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
5. C. Kosmas, M.S. Kallistratos, P. Kopterides Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study J Cancer Res Clin Oncol 134 2008 75 82
6. M. de Forni, M.C. Malet-Martino, P. Jaillais Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study J Clin Oncol 10 1992 1795 1801
7. S.S. Akhtar, K.P. Salim, Z.A. Bano Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study Oncology 50 1993 441 444
8. M. Ng, D. Cunningham, A.R. Norman The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) Eur J Cancer 41 2005 1542 1546
9. R. Labianca, G. Beretta, M. Clerici Cardiac toxicity of 5-fluorouracil: a study on 1083 patients Tumori 68 1982 505 510
10. C. Schöber, E. Papageorgiou, A. Harstrick Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer Cancer 72 1993 2242 2247
11. N. Meydan, I. Kundak, T. Yavuzsen Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up Jpn J Clin Oncol 35 2005 265 270
12. S.A. Jensen, P. Hasbak, J. Mortensen Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle J Clin Oncol 28 2010 5280 5286
13. E. Van Cutsem, P.M. Hoff, J.L. Blum Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil Ann Oncol 13 2002 484 485
14. M.W. Saif, M. Tomita, L. Ledbetter Capecitabine-related cardiotoxicity: recognition and management J Support Oncol 6 2008 41 48
15. P. Alter, M. Herzum, M. Soufi Cardiotoxicity of 5-fluorouracil Cardiovasc Hematol Agents Med Chem 4 2006 1 5
16. N.C. Robben, A.W. Pippas, J.O. Moore The syndrome of 5-fluorouracil cardiotoxicity An elusive cardiopathy Cancer 71 1993 493 499
17. S.A. Jensen, J.B. Sørensen Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine Cancer Chemother Pharmacol 58 2006 487 493
18. T. Südhoff, M.D. Enderle, M. Pahlke 5-Fluorouracil induces arterial vasocontractions Ann Oncol 15 2004 661 664
19. A.J. Burger, S. Mannino 5-Fluorouracil-induced coronary vasospasm Am Heart J 114 1987 433 436
20. Y. Mizuno, Y. Hokamura, T. Kimura A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction Jpn Circ J 59 1995 303 307
21. M.W. Saif, M.M. Shah, A.R. Shah Fluoropyrimidine-associated cardiotoxicity: revisited Expert Opin Drug Saf 8 2009 191 202
22. S.A. Jensen, J.B. Sørensen 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity Cancer Chemother Pharmacol 69 2012 57 64
23. P. Tsibiribi, C. Bui-Xuan, B. Bui-Xuan Cardiac lesions induced by 5-fluorouracil in the rabbit Hum Exp Toxicol 25 2006 305 309
24. B. Patel, R.A. Kloner, J. Ensley 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators Am J Med Sci 294 1987 238 243
25. M. Arellano, M. Malet-Martino, R. Martino The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate Br J Cancer 77 1998 79 86
26. F.L.M. Patterson, R.A. Peters Monofluoro aliphatic compounds F.A. Smith, Handbook of Experimental Pharmacology 1966 Springer-Verlag New York 387 458
27. I. Matsubara, J. Kamiya, S. Imai Cardiotoxic effects of 5-fluorouracil in the guinea pig Jpn J Pharmacol 30 1980 871 879
28. W. Shaib, V. Lee, M.W. Saif Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity In Vivo 23 2009 821 826
29. T. Stewart, N. Pavlakis, M. Ward Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina Intern Med J 40 2010 303 307
30. J. Cerny, A. Hassan, C. Smith Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen Clin Colorectal Cancer 8 2009 55 58
31. G. Cianci, M.F. Morelli, K. Cannita Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity Br J Cancer 88 2003 1507 1509
32. J. Yamamoto, A. Haruno, Y. Yoshimura Effect of coadministration of uracil on the toxicity of tegafur J Pharm Sci 73 1984 212 214
33. D. Yip, C. Karapetis, A.H. Strickland A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies Ann Oncol 14 2003 864 866
34. X.D. Guo, N. Harold, M.W. Saif Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule Cancer Chemother Pharmacol 52 2003 79 85
35. J.C. Marsh, P. Catalano, J. Huang Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer Clin Colorectal Cancer 2 2002 43 50
36. UFT Adverse events reported to the FDA http://www.drugcite.com/?q=UFT Accessed: June 3, 2012
37. J.Y. Douillard, P.M. Hoff, J.R. Skillings Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 2002 3605 3616
38. B.C. Lembersky, H.S. Wieand, N.J. Petrelli Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project Protocol C-06 J Clin Oncol 24 2006 2059 2064
39. K. Shirao, P.M. Hoff, A. Ohtsu Comparison of the efficacy, toxicity and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV J Clin Oncol 22 2004 3466 3474
40. D.G. Haller, J. Cassidy, S.J. Clarke Potential regional differences for the tolerability profiles of fluoropyrimidines J Clin Oncol 24 2008 2059 2064
41. J. Bennouna, M. Saunders, J.Y. Douillard The role of UFT in metastatic colorectal cancer Oncology 76 2009 301 310
42. M. Sellés, P. Castellano, B. Zomora Vasospasm after chemotherapy with 5-fluorouracil [in Spanish] An Med Int 18 2001 2
43. K. Muro, N. Boku, Y. Shimada Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) Lancet Oncol 11 2010 853 860
44. Y.S. Park, H.J. Lim, J. Lee A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer J Clin Oncol 29 Suppl 2011 abstr 3524
45. K. Miura, T. Shirasaka, H. Yamaue S-1 as a core anticancer fluoropyrimidine agent Expert Opin Drug Deliv 9 2012 273 286
46. J. Van den Brande, P. Schöffski, J.H. Schellens EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer Br J Cancer 88 2003 648 653
47. G.J. Peters, P. Noordhuis, A.B. Van Kuilenburg Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors Cancer Chemother Pharmacol 52 2003 1 12
48. Y. Yamada, T. Hamaguchi, M. Goto Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil Br J Cancer 89 2003 816 820
49. B. Reigner, J. Verweij, L. Dirix Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients Clin Cancer Res 4 1998 941 948
50. K. Muneoka, Y. Shirai, N. Yokoyama 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine Int J Clin Oncol 10 2005 441 443
51. N.S. Gunasekara, D. Faulds Raltitrexed A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer Drugs 55 1998 423 435
52. I. Popov, A. Carrato, A. Sobrero Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) Eur J Cancer 44 2008 2204 2211
53. D. Cunningham, J. Zalcberg, U. Rath Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer "Tomudex" Colorectal Cancer Study Group [published erratum appears in: Ann Oncol 1997;8:407] Ann Oncol 7 1996 961 965
54. G. Cocconi, D. Cunningham, E. Van Cutsem Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer Tomudex Colorectal Cancer Study Group J Clin Oncol 16 1998 2943 2952
55. R. Pazdur, M. Vincent Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5- FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized multicenter, North American trial Proc Am Soc Clin Oncol 1997 Abstract 801
56. T.S. Maughan, R.D. James, D.J. Kerr Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial Lancet 359 2002 1555 1563
57. J. Zalcberg Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer Anti Cancer Drugs 8 Suppl 2 1997 S17 S22
58. C. Nutting, A. Folkes The use of raltitrexed (Tomudex) in a patient with 5-FU induced myocardial ischaemia J Clin Oncol 11 1999 66
59. C.H. Köhne, P. Thuss-Patience, M. Friedrich Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-FU Br J Cancer 77 1998 973 977
60. C. Gravalos, C. Garcia-Giron, A. Salud TOMOX compared to FOLFOX 4 as first-line treatment in patients with advanced colorectal cancer (ACRC): results of a multicenter randomised phase II trial ASCO Annual Meeting Proceedings J Clin Oncol 23 June 1 Supplement 2005 Abstract 3563
61. W. Scheithauer, G.V. Kornek, B. Schuell Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy Ann Oncol 12 2001 709 714
62. A. Laudani, V. Gebbia, V. Leonardi Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma Anticancer Res 24 2004 1139 1142
63. K.S. Wilson, C.A. Fitzgerald, J.B. Barnett Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience Cancer Invest 25 2007 711 714
64. C. Carnaghi, L. Rimassa, I. Garassino Irinotecan and raltitrexed: an active combination in advanced colorectal cancer Ann Oncol 13 2002 1424 1429
65. J. Feliu, A. Salud, P. Escudero Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study Br J Cancer 90 2004 1502 1507
66. J. Feliu, C. Castañón, A. Salud Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer Br J Cancer 93 2005 1230 1235
67. J. Aparicio, J.M. Vicent, I. Maestu Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer Ann Oncol 14 2003 1121 1125
68. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group N Engl J Med 343 2000 905 914
69. C.S. Fuchs, M.R. Moore, G. Harker Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 2003 807 814
70. L.J. Oostendorp, P.F. Stalmeier, P.C. Pasker-de Jong Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer Anticancer Drugs 21 2010 749 758
71. E. Van Cutsem, L. Dirix, J.L. Van Laethem Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study Br J Cancer 92 2005 1055 1062
72. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
73. A.F. Sobrero, J. Maurel, L. Fehrenbacher EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
74. A.C. Ashley, D.J. Sargent, S.R. Alberts Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer Cancer 110 2007 670 677
75. L. Fischer von Weikersthal, A. Schalhorn, M. Stauch Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer Eur J Cancer 47 2011 206 214
76. D. Haller, M. Rothenberg, A. Wong Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma J Clin Oncol 26 2008 4544 4550
77. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
78. E. Van Cutsem, M. Peeters, S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664